
USD
$0.00
(0.00%
)At Close (As of Dec 12, 2025)
$5.07M
Market Cap
-
P/E Ratio
-4.51
EPS
$4.58
52 Week High
$0.69
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$183K |
| Total Revenue | $0 |
| Cost Of Revenue | $183K |
| Costof Goods And Services Sold | $183K |
| Operating Income | -$12M |
| Selling General And Administrative | $6.9M |
| Research And Development | $4.7M |
| Operating Expenses | $12M |
| Investment Income Net | - |
| Net Interest Income | $178K |
| Interest Income | $354K |
| Interest Expense | $176K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $183K |
| Income Before Tax | -$11M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$11M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$11M |
| Ebitda | -$11M |
| Net Income | -$11M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$8.3M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $183K |
| Capital Expenditures | $14K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | -$14K |
| Cashflow From Financing | $8.8M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$11M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$183K |
| Total Revenue | $0 |
| Cost Of Revenue | $183K |
| Costof Goods And Services Sold | $183K |
| Operating Income | -$12M |
| Selling General And Administrative | $6.9M |
| Research And Development | $4.7M |
| Operating Expenses | $12M |
| Investment Income Net | - |
| Net Interest Income | $178K |
| Interest Income | $354K |
| Interest Expense | $176K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $183K |
| Income Before Tax | -$11M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$11M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$11M |
| Ebitda | -$11M |
| Net Income | -$11M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Autonomix Medical, Inc. is an innovative medical device company headquartered in The Woodlands, Texas, dedicated to advancing treatments for peripheral nervous system disorders. As a development-stage entity, it focuses on the research and commercialization of proprietary neuromodulation technologies designed to improve patient outcomes in neurology and pain management. With a strong commitment to R&D and a pipeline of cutting-edge solutions, Autonomix aims to position itself as a leader in medical advancements that address critical healthcare challenges.